Consider Timing and Presentation When Telling Kids About Familial Predisposition to Cancer
There are several issues parents should consider before broaching the subject of genetic cancer risk with their children, explains Karen Hurley, a psychologist with the Cleveland Clinic.
Paying It Forward, so Others Do Not Have to Navigate Hereditary Cancer Risk Alone
Finding out that you have a BRCA or other mutation that increases your risk of cancer is a frightening and often confusing prospect, but even one supportive voice can make a huge difference.
Alan Blassberg on Being a Male BRCA Carrier
Alan Blassberg, Director/Producer of Pink and Blue: Colors of Hereditary Cancer, discusses being a male BRCA carrier.
Sharon Bober on Asking Your Doctor About Sexual Health
Sharon Bober, PhD, discusses how patients can ask their doctors about sexual health.
Understanding Mastectomy and Reconstruction Options Can Ease Difficult Decisions
Those considering mastectomy to help prevent inherited breast cancer, or because they’ve been diagnosed with the disease, are likely to find themselves sorting through a host of complex questions.
Less Invasive Techniques Gaining Traction in Ovarian Cancer Prevention
For women genetically predisposed to ovarian cancer, prevention is extremely important. But what are the most effective and least invasive prevention techniques, and when is the best time in life to employ them?
All in the Family: The Importance of Talking About Hereditary Cancer
Knowing that you have an inherited gene mutation can allow you and your family members to look into prevention or detect a cancer at an early stage.
Angela Fishbaugh on Discovering Your Story and Skills
Angela Fishbaugh, author of "Angela's Decision," discusses how to discover your skills and story within.
Extending Progression-Free Survival in BRCA-Positive Breast Cancer
“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.
Ilana Cass on Potential Consequences of Preventive Surgery
Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.
Being a 'FORCE' In Hereditary Cancers for 18 Years: An Interview with Executive Director Sue Friedman
Sue Friedman, executive director and founder of FORCE, is a hereditary breast cancer survivor herself and has been concentrating on being the support system for others that she didn’t have when she was going through her battle 20 years ago.
XRAYS Separates the Help from the Hype to Make Sense of Cancer Research in the News
The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.
Ethical Dilemmas Arise from Genetic Testing for Cancer
While genetic testing for cancer has some obvious benefits, it also creates ethical dilemmas in many cases.
Nail Bed Balm Proves Successful in Preventing Chemotherapy-Related Nail Damage
PolyBalm was effective in mitigating chemotherapy-related nail damage, according to a recent study presented at ASCO.
Promising Combination Moves Into Kidney Cancer
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.
Drug Combination Is Effective in Urothelial Carcinoma
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
Therapy Shows High Remission Rates in Multiple Myeloma
Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.
Will There Be an Immunotherapy Approval in Gastric Cancer?
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
New Agent Shows Promise Across Many Cancers Which Have TRK Fusion Mutations
Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.
With Patients Reporting Symptoms Using Web Tool, Survival Improves
An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.
Patients With Low-Risk Colon Cancer Can Have Less Chemotherapy, Reducing Neuropathy
According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.
Staying CALM: Psychotherapy for Patients with Advanced Cancers
The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.
Maintaining Mobility May Not Require More Than Single-Dose Radiation
According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.
Study Finds a Decline in Late Effects After Childhood Treatment
There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.
Psychological Interventions Can Lower Fear of Recurrence
A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.
Combination Improves Breast Cancer Survival, Study Shows
Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.
Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
Improving Survival in BRCA-Proficient Ovarian Cancer
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.
Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
2 Clarke Drive Cranbury, NJ 08512